Rovalpituzumab Tesirine

A Long-Term Study of Rovalpituzumab Tesirine

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody-drug Conjugate

Upfront Cash : Inapplicable

June 01, 2018

Lead Product(s) : Rovalpituzumab Tesirine

Therapeutic Area : Oncology

Highest Development Status : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

02

AbbVie Inc

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Rovalpituzumab Tesirine

Therapeutic Area : Oncology

Study Phase : Undisclosed

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Expanded Access to Rovalpituzumab Tesirine

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody-drug Conjugate

Upfront Cash : Inapplicable

April 20, 2018

Lead Product(s) : Rovalpituzumab Tesirine

Therapeutic Area : Oncology

Highest Development Status : Undisclosed

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

03

AbbVie Inc

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Rovalpituzumab Tesirine

Therapeutic Area : Oncology

Study Phase : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurren...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody-drug Conjugate

Upfront Cash : Inapplicable

March 22, 2017

Lead Product(s) : Rovalpituzumab Tesirine

Therapeutic Area : Oncology

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

04

AbbVie Inc

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Rovalpituzumab Tesirine

Therapeutic Area : Oncology

Study Phase : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lu...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody-drug Conjugate

Upfront Cash : Inapplicable

February 23, 2017

Lead Product(s) : Rovalpituzumab Tesirine

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

05

AbbVie Inc

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Rovalpituzumab Tesirine

Therapeutic Area : Oncology

Study Phase : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody-drug Conjugate

Upfront Cash : Inapplicable

January 26, 2017

Lead Product(s) : Rovalpituzumab Tesirine

Therapeutic Area : Oncology

Highest Development Status : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

06

AbbVie Inc

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Rovalpituzumab Tesirine

Therapeutic Area : Oncology

Study Phase : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Sma...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody-drug Conjugate

Upfront Cash : Inapplicable

June 30, 2016

Lead Product(s) : Rovalpituzumab Tesirine

Therapeutic Area : Oncology

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

07

AbbVie Inc

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Rovalpituzumab Tesirine

Therapeutic Area : Oncology

Study Phase : Phase I/ Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody-drug Conjugate

Upfront Cash : Inapplicable

March 16, 2016

Lead Product(s) : Rovalpituzumab Tesirine

Therapeutic Area : Oncology

Highest Development Status : Phase I/ Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

08

AbbVie Inc

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Rovalpituzumab Tesirine

Therapeutic Area : Oncology

Study Phase : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or R...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody-drug Conjugate

Upfront Cash : Inapplicable

February 04, 2016

Lead Product(s) : Rovalpituzumab Tesirine

Therapeutic Area : Oncology

Highest Development Status : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable